Haemonetics (HAE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $126.97 +5.56%
Revenue Growth %: +5.6%
Financial Fact:
Net income: 0.38
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +5.6%
Financial Fact:
Net income: 0.38
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $343.29 million versus the consensus estimate of $329.47 million.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Datadog shares drop on weak Q4 revenue outlook
- Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
